secwatch.observer — SEC 8-K summary
======================================

Issuer:     LeonaBio, Inc. (LONA)
CIK:        0001620463
Form:       8-K
Filed at:   2022-10-17T23:59:59+00:00
Accession:  0000950170-22-019592
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Athira gets positive interim analysis for Alzheimer's drug fosgonimeton, study continues
--------------------------------------------------------------------------------

- Independent data monitoring committee recommended continuation of LIFT-AD after unblinded interim analysis.
- Adding fewer than 150 patients (total <300 with no background therapy) will power study for primary endpoint.
- Interim analysis in ~100 patients not on background therapy corroborated prior ACT-AD Phase 2 findings.
- Company targets enrollment completion mid-2023 and topline data in early 2024.
- CEO cites strong balance sheet to execute through key data readouts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1620463/000095017022019592/0000950170-22-019592-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1620463/000095017022019592/atha-20221017.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-019592

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer